5 unknown, 2 completed, 2 recruiting. 4 Phase 2, 2 Not applicable, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Not applicable | 2 | Unknown 2 |
| Phase 3 | 2 | Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow aclacinomycins: new trials by email Literature Review of aclacinomycins trials Research Report on aclacinomycins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia the standard "3+7" regimen, Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte - Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients | Phase 3 | Recruiting | Chinese PLA General Hospital | 120 | 2024-11-18 | 2026-08-20 |
| Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients Selinexor, Homoharringtonine, Cytarabine - Relapsed/Refractory AML | Not applicable | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2023-05-01 | 2023-05-06 |
| Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia Venetoclax - Refractory/Relapse Acute Myeloid Leukemia | Phase 2 | Unknown | Hematology department of the 920th hospital | 42 | 2023-02-01 | 2023-04-11 |
| Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Selinexor, Homoharringtonine, Daunorubicin - Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Recruiting | Shanxi Bethune Hospital | 50 | 2023-01-29 | 2024-10-22 |
| Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Decitabine, Daunorubicin, Cytarabine, Mitoxantrone, Cytarabine - Acute Myeloid Leukemia | Phase 4 | Unknown | The First Hospital of Jilin University | 180 | 2017-01-01 | 2017-01-20 |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia Cladribine, G-CSF, Aclarubicin - Acute Myeloid Leukemia, Relapse Leukemia | Phase 2 | Unknown | Sun Yat-sen University | 48 | 2016-01-01 | 2019-08-20 |
| Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF), low dose cytarabine - Acute Myeloid Leukemia | Not applicable | Unknown | Jianxiang Wang | 300 | 2015-04-01 | 2016-10-07 |
| Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML Decitabine 20 mg/m²/day for 5 days - AML | Phase 2 | Completed | Chinese PLA General Hospital | 30 | 2015-04-01 | 2019-06-10 |
| Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML) Decitabine, Cytarabine, aclacinomycin - MDS, AML | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 29 | 2012-11-01 | 2016-02-25 |
Leukemia, Myeloid, Acute (6) · Recurrence (1)
Chinese PLA General Hospital (3) · Hematology department of the 920th hospital (1) · Jianxiang Wang (1) · Shanxi Bethune Hospital (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Soochow University (1) · The First Hospital of Jilin University (1)
China (9)
Dahong Liu, Doctor (1) · Li Yu, M.D. Ph.D. (1) · Liang Wang, M.D. (1) · Su J Gao, PhD (1) · Tao Wang (1)